Sequana shares surge after FDA approval for alfapump
The US Food and Drug Administration (FDA) has approved Sequana Medical’s alfapump for the treatment of recurrent or refractory ascites…
Metabolic Disorders
-
-
Vivani begins exenatide implant trial for obesity in Australia
Vivani Medical has commenced the first-in-human, randomised trial, LIBERATE-1, by initiating screening and enrolment to assess the pharmacokinetic and safety…
-
ClearNote and Southampton researchers partner for pancreatic cancer test study
ClearNote Health has announced a partnership with the University of Southampton's Clinical Trials Unit researchers to use the Avantect pancreatic…
-
“No magic wand” for Novo Nordisk, as CagriSema pen supply rumours swirl
Against a backdrop of manufacturing prioritisation, Novo Nordisk’s contract with Swiss medical technology Ypsomed could include the supply of injection…
-
Medtronic’s insulin pen app gains FDA clearance
Medtronic has received clearance from the US Food and Drug Administration (FDA) for its new InPen app, paving the way…
-
ReShape secures NIH grant to develop electrodes for diabetes treatment device
ReShape Lifesciences has received a $241,000 grant from the US National Institutes of Health (NIH) to develop electrodes for its…
-
Allurion boasts over 17% weight loss with swallowable balloon device
Allurion Technologies has presented data from two studies showing the efficacy of its swallowable gastric balloon in causing significant weight…
-
Oxford Medical Products touts positive safety data for ‘mechanical’ weight loss pill
The surge of popularity of weight loss drugs has created a rivalry with traditional device orientated approaches, but a new…
-
Noom unveils body scan technology to combat muscle loss of GLP-1 treatment
Noom has unveiled body scan technology that it says will help monitor and manage muscle mass loss in patients taking…
-
Allurion’s swallowable balloon hits trial success amid weakening financials
Allurion’s intragastric balloon has demonstrated yet more positive efficacy and safety results in a study on patients living obesity, though…
